Στεφ. Νόσος-Καρδιακή Ανεπάρκεια

20 Aug

Posted at 09:40h in Στεφ. Νόσος-Καρδιακή Ανεπάρκεια by

George C. Sutton a, Jan Erik Otterstad b, Bridget-Anne Kirwan c, Zoltán Vokó d, Sophie de Brouwer c, Jacobus Lubsen c,e, Philip A. Poole-Wilson a,⁎ On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators Cardiac Medicine, National Heart and Lung Institute, Imperial College...

20 Aug

Posted at 09:40h in Στεφ. Νόσος-Καρδιακή Ανεπάρκεια by

ohn J.V. McMurray, MB, MD,a James B. Young, MD,b Mark E. Dunlap, MD,c Christopher B. Granger, MD,d James Hainer, MD,e Eric L. Michelson, MD,e Steven Earle, PhD,e Bertil Olofsson, PhD,f Jan O¨ stergren, MD,g Salim Yusuf, MD, DPhil,h Karl Swedberg, MD, PhD,i and Marc A....

20 Aug

Posted at 09:38h in Στεφ. Νόσος-Καρδιακή Ανεπάρκεια by

Norman M. Kaplan At least in hypertension, there has never been a perfect clinical trial. By its nature, hypertension poses several barriers to the performance and interpretation of even the most carefully planned and conducted therapeutic trial. First and perhaps foremost, blood pressure is a constantly...

20 Aug

Posted at 09:36h in Στεφ. Νόσος-Καρδιακή Ανεπάρκεια by

Thomas Giles Ambulatory blood pressure monitoring enables the recording of the circadian rhythm of blood pressure under everyday circumstances, with the majority of individuals displaying diurnal variations in both systolic and diastolic blood pressures. During sleep, blood pressure in most people is between 10% and 20%...

20 Aug

Posted at 09:30h in Στεφ. Νόσος-Καρδιακή Ανεπάρκεια by

Jennifer G. Robinson, MD, MPH, and Nidhi Maheshwari, MBBS A "polypill" for the primary prevention of cardiovascular disease has been proposed. We estimated the projected benefit of a secondary prevention "poly-portfolio" strategy, including pharmacologic and lifestyle approaches for those with coronary heart disease (CHD) or stroke....